Research and Markets: Tourette Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Sun-Herald.com
May 3, 2012

DUBLIN -- - Research and Markets has announced the addition of GlobalData's new report "Tourette Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019" to their offering.
GlobalData, the industry analysis specialist, has released its new report, Tourette Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global Tourette Syndrome Therapeutics market. The report identifies the key trends shaping and driving the global Tourette Syndrome Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders.
Most importantly, the report provides valuable insights on the pipeline products within the global Tourette Syndrome Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

The Tourette Syndrome Therapeutics Market is Forecast to Decline until 2019
GlobalData's analysis shows that the global Tourette Syndrome (TS) therapeutics market was valued at $170.8m in 2011, and is forecast to decline at a Compound Annual Growth Rate (CAGR) of -3.3% to $130m by 2019. The current therapeutics market is served by approved drugs such as haloperidol and pimozide and off-label drugs such as Abilify (aripiprazole), risperidone, clonidine and tetrabenazine. Unlike the forecast period, the historic period saw growth at a CAGR of 0.2%, from $168.8m in 2006 to $170.8m in 2011. This low growth can be attributed to the patent expiry of the off-label drug risperidone in 2007.

Despite the increasing diseased population and rising treatment rates, the TS therapeutics market is expected to decline during the forecast period. This is primarily attributed to the patent expiry of the highly-priced off-label drug Abilify in 2014. There are no pipeline products which are expected to significantly impact the market during the forecast period. Abilify (OPC-14597) is in Phase III in the US and at the New Drug Application (NDA) filing stage in Asia.

Companies Mentioned:
- Otsuka Holdings Co., Ltd